Jasper Therapeutics Stock Analysis

JSPR Stock  USD 3.14  0.13  3.98%   
Jasper Therapeutics is undervalued with Real Value of 14.85 and Target Price of 50.11. The main objective of Jasper Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Jasper Therapeutics is worth, separate from its market price. There are two main types of Jasper Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Jasper Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Jasper Therapeutics is usually not traded on Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday. Jasper Stock trading window is adjusted to America/New York timezone.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
To learn how to invest in Jasper Stock, please use our How to Invest in Jasper Therapeutics guide.

Jasper Stock Analysis Notes

About 90.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.12. Some equities with similar Price to Book (P/B) outperform the market in the long run. Jasper Therapeutics recorded a loss per share of 5.27. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 4th of January 2024. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Jasper Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 35 people. To learn more about Jasper Therapeutics call Ronald Martell at 650 549 1400 or check out https://jaspertx.com.

Jasper Therapeutics Investment Alerts

Jasper Therapeutics generated a negative expected return over the last 90 days
Jasper Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (71.27 M) with profit before overhead, payroll, taxes, and interest of 0.
Jasper Therapeutics currently holds about 60.81 M in cash with (62.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.6.
Jasper Therapeutics has a poor financial position based on the latest SEC disclosures
Over 90.0% of the company shares are owned by institutional investors
Latest headline from gurufocus.com: INVESTOR ALERT Pomerantz Law Firm Investigates ClaimsOn Behalf

Jasper Therapeutics Upcoming and Recent Events

13th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Jasper Largest EPS Surprises

Earnings surprises can significantly impact Jasper Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-09
2024-06-30-1.09-0.970.1211 
2024-11-07
2024-09-30-1.07-1.24-0.1715 
2024-05-14
2024-03-31-1.23-1.030.216 
View All Earnings Estimates

Jasper Therapeutics Environmental, Social, and Governance (ESG) Scores

Jasper Therapeutics' ESG score is a quantitative measure that evaluates Jasper Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Jasper Therapeutics' operations that may have significant financial implications and affect Jasper Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Jasper Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Ubs Group Ag2025-03-31
534.6 K
Kingdon Capital Management Llc2025-03-31
490 K
Citadel Advisors Llc2025-03-31
375.2 K
Bank Of America Corp2025-03-31
360.7 K
Geode Capital Management, Llc2025-03-31
263.7 K
Goldman Sachs Group Inc2025-03-31
233.8 K
State Street Corp2025-03-31
227.9 K
Deutsche Bank Ag2025-03-31
169.3 K
Lion Point Capital, Lp2025-03-31
146.5 K
Soleus Capital Management, L.p.2025-03-31
1.5 M
Velan Capital Investment Management Lp2025-03-31
1.4 M
Note, although Jasper Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Jasper Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 47.32 M.

Jasper Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.89)(0.94)
Return On Capital Employed(1.18)(1.24)
Return On Assets(0.89)(0.94)
Return On Equity(1.16)(1.10)

Management Efficiency

Jasper Therapeutics has return on total asset (ROA) of (0.565) % which means that it has lost $0.565 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0134) %, meaning that it created substantial loss on money invested by shareholders. Jasper Therapeutics' management efficiency ratios could be used to measure how well Jasper Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/24/2025, Return On Tangible Assets is likely to drop to -0.94. In addition to that, Return On Capital Employed is likely to drop to -1.24. At this time, Jasper Therapeutics' Net Tangible Assets are relatively stable compared to the past year. As of 07/24/2025, Non Current Assets Total is likely to grow to about 4.6 M, while Total Assets are likely to drop slightly above 67.4 M.
Last ReportedProjected for Next Year
Book Value Per Share 4.23  4.44 
Tangible Book Value Per Share 4.23  4.44 
Enterprise Value Over EBITDA(3.39)(3.22)
Price Book Value Ratio 5.06  5.31 
Enterprise Value Multiple(3.39)(3.22)
Price Fair Value 5.06  5.31 
Enterprise Value217.8 M228.7 M
Effective leadership at Jasper Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta
2.697
Return On Assets
(0.56)
Return On Equity
(1.01)

Technical Drivers

As of the 24th of July, Jasper Therapeutics retains the Market Risk Adjusted Performance of 0.1113, risk adjusted performance of 0.0316, and Downside Deviation of 10.83. Jasper Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Jasper Therapeutics variance and potential upside to decide if Jasper Therapeutics is priced fairly, providing market reflects its last-minute price of 3.14 per share. Given that Jasper Therapeutics has jensen alpha of (0.22), we strongly advise you to confirm Jasper Therapeutics's regular market performance to make sure the company can sustain itself at a future point.

Jasper Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Jasper Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Jasper Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Jasper Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jasper Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jasper Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Jasper Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Tucker Edwin Jonathan over a month ago
Acquisition by Tucker Edwin Jonathan of 90000 shares of Jasper Therapeutics at 6.0 subject to Rule 16b-3
 
Klein Lawrence Otto over three months ago
Acquisition by Klein Lawrence Otto of 78045 shares of Jasper Therapeutics at 3.54 subject to Rule 16b-3
 
Kapoor Vishal over three months ago
Acquisition by Kapoor Vishal of 47000 shares of Jasper Therapeutics at 1.6 subject to Rule 16b-3
 
Mahal Jeetinder Singh over six months ago
Disposition of 900 shares by Mahal Jeetinder Singh of Jasper Therapeutics at 24.155 subject to Rule 16b-3
 
Mahal Jeetinder Singh over six months ago
Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3
 
Martell Ron over six months ago
Disposition of 87531 shares by Martell Ron of Jasper Therapeutics at 1.46 subject to Rule 16b-3
 
Mahal Jeetinder Singh over six months ago
Acquisition by Mahal Jeetinder Singh of 900 shares of Jasper Therapeutics at 7.1 subject to Rule 16b-3
 
Martell Ron over six months ago
Disposition of 87531 shares by Martell Ron of Jasper Therapeutics at 1.46 subject to Rule 16b-3
 
Carlyle Group Inc. over six months ago
Discretionary transaction by Carlyle Group Inc. of 78045 shares of Jasper Therapeutics at 3.54 subject to Rule 16b-3
 
Lis William over a year ago
Acquisition by Lis William of 89972 shares of Jasper Therapeutics at 3.54 subject to Rule 16b-3
 
Martell Ron over a year ago
Acquisition by Martell Ron of 10000 shares of Jasper Therapeutics at 23.95 subject to Rule 16b-3
 
Tucker Edwin Jonathan over a year ago
Acquisition by Tucker Edwin Jonathan of 400 shares of Jasper Therapeutics at 4.1735 subject to Rule 16b-3

Jasper Therapeutics Outstanding Bonds

Jasper Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Jasper Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Jasper bonds can be classified according to their maturity, which is the date when Jasper Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Jasper Therapeutics Predictive Daily Indicators

Jasper Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Jasper Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Jasper Therapeutics Forecast Models

Jasper Therapeutics' time-series forecasting models are one of many Jasper Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Jasper Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Jasper Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Jasper Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Jasper shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Jasper Therapeutics. By using and applying Jasper Stock analysis, traders can create a robust methodology for identifying Jasper entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Jasper Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Jasper analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Jasper analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
50.11Strong Buy11Odds
Jasper Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Jasper analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Jasper stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Jasper Therapeutics, talking to its executives and customers, or listening to Jasper conference calls.
Jasper Analyst Advice Details

Jasper Stock Analysis Indicators

Jasper Therapeutics stock analysis indicators help investors evaluate how Jasper Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Jasper Therapeutics shares will generate the highest return on investment. By understating and applying Jasper Therapeutics stock analysis, traders can identify Jasper Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow87.3 M
Common Stock Shares Outstanding14.6 M
Total Stockholder Equity61.7 M
Total Cashflows From Investing Activities-532 K
Property Plant And Equipment Net2.9 M
Cash And Short Term Investments71.6 M
Cash71.6 M
Accounts PayableM
Net Debt-69.8 M
50 Day M A4.9119
Total Current Liabilities15.2 M
Other Operating Expenses76.2 M
Non Current Assets Total4.1 M
Non Currrent Assets Other1.2 M
Stock Based Compensation6.6 M

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.